drugset / Trial / NCT02290431

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

NCT02290431

Phase 2 Completed 31 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of panobinostat in combination with bortezomib and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.

Timeline

Start
2014-12-16
Primary completion
2017-12-29
Completion
2018-12-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.3 mg/m2 Subcutaneous
Subject Dexamethasone Small molecule 20 mg Oral
Subject Panobinostat Small molecule 20 mg Oral